Review

Lessons from Epidemiologic Research about Risk Factors, Modifiers, and Progression of Late Onset Alzheimer’s Disease in New York City at Columbia University Medical Center

Devangere Devananda, Joseph Lee, Jose Luchsinger, Jennifer Manly, Karen Marden, Richard Mayeux, Nikolaos Scarmeas, Nicole Schupf, and Yaakov Stern

Abstract. This review summarizes the findings and importance of 12 articles from research at Columbia University in New York City that were among the most cited in the literature between 2006 and 2011. The 12 articles summarized in this review made important contributions to the field of Alzheimer’s disease in the last 5 years. Four of the articles established the Mediterranean diet as a food consumption pattern that may prevent Alzheimer’s disease in addition to physical activity. Two of the articles advanced our knowledge of predictors of conversion from mild cognitive impairment to dementia. Four of the articles provided important knowledge of risk factors for the progression of Alzheimer’s disease and its complications. Lastly, one of the articles laid the theoretical framework for the study of cognitive reserve, an important modifier of the manifestation of Alzheimer’s disease. These studies have advanced our knowledge about risk factors, modifiers, and progression of late onset Alzheimer’s disease.

Keywords: Alzheimer’s disease, conversion, diet, cognitive reserve, epidemiology, genes, mild cognitive impairment, predictors, progression, risk factors

Correspondence to: Jose A. Luchsinger, MD, MPH, Columbia University Medical Center, PHF Center, room 210, 630 West 168th Street, New York, NY 10032, USA. Tel.: +1 212 305-4730; E-mail: jal94@columbia.edu.

This review summarizes the findings and importance of 12 articles [1–12] from research at Columbia University in New York City that were among the most cited in the literature between 2006 and 2011. The determination of citations was made using
These studies come from three different cohorts based at Columbia University Medical Center in New York City. These cohorts are:

- **The Washington Heights Columbia Aging Project (WHICAP; PI: Richard Mayeux)** is comprised of two related community-based cohorts, one recruited from 1992 to 1994 [13], and one recruited from 1999 to 2001 [14]. Subjects in WHICAP were 65 years and older at the time of recruitment, were enrolled in Medicare, and were from three ethnic groups: Hispanics, non-Hispanic blacks, and non-Hispanic whites. The main goal of WHICAP is to study the epidemiology and predictors of cognitive disorders in an urban multietnic cohort.

- **The Predictors Study (PI: Yaakov Stern)** is a community-based cohort study of persons with a diagnosis of Alzheimer’s disease (AD) followed prospectively. The main goal of the predictors study is to characterize the progression of AD and identify modifiers of progression.

- **The Questionable Dementia 1 study (QD; PI: Devangere Devanand)**, a cohort study of persons with a diagnosis of mild cognitive impairment (MCI), recruited from a referral memory disorders clinic. The goal of the QD1 study is to identify predictors of progression to dementia among persons with MCI.

Among the 12 most cited articles that resulted from these studies, four reported on modifiable risk factors for AD [1–4], one reported on genetic risk factors for AD [10], two reported on predictors of conversion of MCI to AD [7, 9], four reported on progression of AD [5, 6, 11, 12], and one was a review article on an important modifier of AD risk—cognitive reserve [8]. This article is organized following these themes. We provide summaries of each article, put the findings in perspective, and briefly discuss their importance to the field.

**STUDIES OF GENETIC RISK FACTORS FOR LATE ONSET ALZHEIMER’S DISEASE**

One of the 12 studies examined the relationship of a novel genetic risk factor, SORL1, with AD [10]. Variants in 3′ and 5′ regions of SORL1, the neuronal sorting protein-related receptor, have been found to be associated with late onset familial and sporadic AD in several datasets that were selected for familial aggregation or were ethnically diverse or clinic-based selected series. Our nested case-control study was performed using...
Table 1
Summary of most cited articles of risk factors for late onset Alzheimer’s disease from Columbia University in New York City. These manuscripts were based in the Washington Heights Inwood Columbia Aging Project (WHICAP; PI: R. Mayeux).

<table>
<thead>
<tr>
<th>Study [Ref]</th>
<th>Participants/design</th>
<th>Exposures/outcomes</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>N Scarmeas, Y Stern, MX Tang, B Mayeux, JA Luchsinger (2006) Mediterranean diet and risk of Alzheimer’s disease. [1]</td>
<td>2,258 community-based nondemented individuals aged 65 years and older followed prospectively every 1.5 years</td>
<td>Adherence to the MeDi (0–9 point scale with higher scores indicating higher adherence) was the main predictor in models that were adjusted for cohort, age, gender, ethnicity, education, APOE genotype, caloric intake, smoking, medical morbidty index, and BMI. The outcome was incident AD.</td>
<td>There were 262 incident AD cases during the course of 4 (±3.0, 0.2–13.9) years of follow-up. Higher adherence to the MeDi was associated with lower risk of AD (HR, 0.91; 95% CI 0.83–0.98; p = 0.015). Compared to subjects in the lowest MeDi tertile, subjects in the middle MeDi tertile had a HR of 0.85 (0.63–1.16) and those at the highest tertile a HR of 0.60 (0.42–0.87) for AD (p for trend &lt;0.001)</td>
</tr>
<tr>
<td>N Scarmeas, JA Luchsinger, N Schupf, AM Brickman, S Cosentino, MX Tang, Y Stern (2009) Physical activity, diet and risk of Alzheimer’s disease. [4]</td>
<td>1,880 community-dwelling elders without dementia with both diet and PA information available followed prospectively every 1.5 years</td>
<td>Adherence to the MeDi (0–9 scale trichotomized into low-middle-high or dichotomized into low-high) and PA (sum of weekly participation in a variety of physical activities, weighted by the type of activity (light, moderate, vigorous) trichotomized into none-some-much or dichotomized into low-high), separately and combined, were the main predictors in Cox models. Models were adjusted for cohort, age, gender, ethnicity, education, APOE genotype, caloric intake, BMI, smoking, depressive symptoms, leisure activities, a comorbidity index, and baseline clinical dementia rating. The outcome was AD.</td>
<td>A total of 282 incident AD cases occurred during 5.4 (±3.3) years of follow-up. When considered simultaneously, both MeDi adherence (HR for middle 0.98 [0.72–1.33]; HR for high 0.60 [0.42–0.87]; p for trend &lt;0.001) and PA (HR for some 0.75 [0.50–1.14]; HR for much 0.87 [0.47–1.67]; p for trend 0.05) were associated with lower AD risk. As compared with individuals neither adhering to the MeDi nor exercising (low-low; absolute AD risk 19%), those either adhering to the MeDi or exercising (low-high or high-high) had a lower risk (absolute risk 13%, HR 0.75; 0.56–0.95) for developing AD, while those both adhering to the MeDi and exercising (high-high) had an even lower risk (absolute risk 12%, HR 0.56; 0.40–0.78; p for trend &lt;0.001)</td>
</tr>
<tr>
<td>N Scarmeas, Y Stern, R Mayeux, JA Luchsinger (2006) Mediterranean diet, Alzheimer’s disease and vascular mediation. [3]</td>
<td>A case-control study nested within WHICAP: 194 AD patients versus 1,790 non-demented</td>
<td>Adherence to the MeDi (0–9 point scale with higher scores indicating higher in logistic regression models that were adjusted for cohort, age, gender, ethnicity, education, APOE genotype, caloric intake, smoking, medical morbidity index, and BMI. The outcome was AD. Mediation was evaluated by examining the attenuation of the OR with the introduction of vascular variables</td>
<td></td>
</tr>
<tr>
<td>N Scarmeas, Y Stern, R Mayeux, JI Manly, NSchupf, JA Luchsinger (2006) Mediterranean diet and mild cognitive impairment. [2]</td>
<td>There were 1,393 cognitively normal participants, 275 of whom developed MCI during 4.3 (±2.7, 0.9–19.8) years of follow-up. There were 482 subjects with MCI, 106 of whom developed AD during 4.3 (±2.7, 1.0–13.8) years of follow-up. Participants were followed every 1.5 years</td>
<td>We used Cox proportional hazards to investigate the association between adherence to the MeDi (0–9 scale: higher scores higher adherence) and (1) incidence of MCI and (2) progression from MCI to AD. All models were adjusted for cohort, age, gender, ethnicity, education, APOE genotype, caloric intake, BMI, and time duration between baseline dietary assessment and baseline diagnosis</td>
<td></td>
</tr>
</tbody>
</table>

AD, Alzheimer’s disease; APOE, apolipoprotein E; BMI, body mass index; HR, hazards ratio; MCI, mild cognitive impairment; MeDi, Mediterranean diet; OR, odds ratio; PA, physical activity.
the community-based WHICAP study. There were 296 patients with probable AD and 428 healthy elderly controls. The participants were of African American (34%), Caribbean Hispanic (51%), or non-Hispanic whites (15%). Several individual single-nucleotide polymorphisms (SNPs) and SNP haplotypes were significantly associated with AD in this prospectively collected community-based cohort, confirming the previously reported positive association of SORL1 with AD. SNP 12 near the 3′ region was associated with AD in African-Americans and Hispanics. Two SNPs in the 3′ region were also associated with AD in African-Americans (SNP 26) and whites (SNP 20). A single haplotype C-C-A at SNPs 4–6 was associated with AD in Hispanics. However, several different haplotypes were associated with AD in the African-Americans and whites, including the haplotype T-T-C at SNPs 23–25 (p = 0.035) that was significantly associated with AD in the North European whites in a previous report.

The contributions of this article to the field included the confirmation of the association between AD and variants in the SORL1 gene in a population based multiethnic cohort. Also, the discovery of significant association in multiple regions of the gene, and the discovery of different AD-associated haplotypes different from those in other studies revealed that there may be a high degree of allelic heterogeneity, with disease-associated variants occurring on multiple different haplotypic backgrounds. Thus, second attempts to identify the pathogenic variants in SORL1 will likely have to investigate larger regions of the SORL1 gene than simply just between SNPs 8–10 and 22–25. This study is part of a larger effort in genetic epidemiology research in which our group participates that has established SORL1 as one of the most important genetic risk factors for AD [17, 21] after APOE e4. Late onset AD is increasing recognized as a complex heterogeneous condition in which multiple pathways and factors are likely to be involved. The discovery of new genetic factors in late onset AD, in this case SORL1, is providing new insights into these pathways.

STUDIES OF CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE

Two of the 12 articles [7, 9] (Table 2) summarized in this review reported neuropsychological and imaging predictors of conversion from non-dementia cognitive impairment to AD in the QD1 study. QD1 was a cohort based in a memory disorders clinic, as compared with the studies of non-genetic and genetic risk factors previously described, which were community based.

The first article [7] evaluated conversion rates to AD in subtypes of MCI and identified neuropsychological measures most predictive of the time to conversion. This study demonstrated that mildly cognitively impaired patients with memory plus other cognitive domain deficits, rather than those with pure amnestic MCI, constituted the high risk group for conversion. Deficits in verbal memory and psychomotor speed/execution function abilities strongly predicted conversion to AD. This study raised the intriguing possibility that these amnestic-"plus" patients constitute a group at high risk for conversion to AD, whereas the pure amnestic MCI patients may not be at such a high risk. However, with longer follow-up, the pure amnestic MCI patients may develop multiple cognitive domain deficits and eventually convert to AD.

These findings also suggest that testing for deficits in multiple cognitive domains in addition to those in memory improves the predictive value of neuropsychological testing in patients with MCI. The study showed that combining commonly used neuropsychological tests strongly predicted conversion from MCI to AD, emphasizing the critical role of cognitive testing in evaluation and prediction of outcome in patients with MCI.

The second article [9] evaluated the utility of magnetic resonance imaging (MRI) hippocampal and entorhinal cortex size in predicting conversion from MCI to AD. Hippocampal and entorhinal cortex volumes were each largest in controls, intermediate in MCI non-converters, and smallest in MCI converters to AD. Smaller hippocampal volume and entorhinal cortex volume each predicted time to conversion to AD. This study raised the intriguing possibility that these amnestic-"plus" patients constitute a group at high risk for conversion to AD, whereas the pure amnestic MCI patients may not be at such a high risk. However, with longer follow-up, the pure amnestic MCI patients may develop multiple cognitive domain deficits and eventually convert to AD.

The second article [9] evaluated the utility of magnetic resonance imaging (MRI) hippocampal and entorhinal cortex size in predicting conversion from MCI to AD. Hippocampal and entorhinal cortex volumes were each largest in controls, intermediate in MCI non-converters, and smallest in MCI converters to AD. Smaller hippocampal volume and entorhinal cortex volume each predicted time to conversion to AD. Similar results were obtained for hippocampal and entorhinal cortex volume in patients with MCI with Mini-Mental State Exam (MMSE) scores ≥27/30 (21% converted to AD) and in the subset of patients with amnestic MCI (35% converted to AD). In the total patient sample, when both hippocampal and entorhinal volume were entered into an age-stratified Cox model with gender, MMSE, education, and intracranial volume, smaller hippocampal volume and entorhinal cortex volume predicted time to conversion to AD. Similar results were obtained in a Cox model that also included neuropsychological test scores. Based on logistic regression models in the 3-year follow-up sample, for a fixed specificity of 80%, the addition of hippocampal and entorhinal cortex volumes to
Table 2
Summary of most cited articles of predictors of conversion from mild cognitive impairment to Alzheimer’s disease. These studies were based in a clinic based cohort of persons with mild cognitive impairment (PI: D. Devanand)

<table>
<thead>
<tr>
<th>Study</th>
<th>Participants/design</th>
<th>Exposures/outcomes</th>
<th>Findings</th>
</tr>
</thead>
</table>
| MH Tabert, JI Manly, X Liu, GH Pelton, S Rosenbloom, M Jacobs, D Zamora, M Goodkind, KB Bell, Y Stern, DP Devanand(2006) Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. [7] | 148 patients reporting memory problems and 63 group-matched controls. Patients were followed up semiannually and controls annually | Subtypes of MCI were determined by using demographically adjusted regression norms on neuropsychological tests. Survival analysis was used to identify the most predictive neuropsychological measures. The outcome was a consensus diagnosis of probable AD. | At baseline, 108 patients met criteria for amnestic MCI. 117 had memory plus other cognitive domain deficits and 21 had pure memory deficits. The mean duration of follow-up for the 148 patients was 46.6±24.6 months. In 3 years, 32 (50.0%) of 64 amnestic (“plus”) and 2 (10.0%) of 20 “pure” amnestic patients converted to AD (p<0.001). In 148 patients, of 5 a priori predictors, the percent savings from immediate to delayed recall on the SRT and the WAIS-R Digit Symbol were the strongest predictors of time to conversion. The entire neuropsychological test battery, a stepwise selection procedure retained 2 measures in the final model: total immediate recall on the SRT (OR per 1-point decrease, 1.10; 95% CI, 1.05–1.14; p<0.001) and WAIS-R Digit Symbol coding (OR, 1.06; 95% CI, 1.01–1.11; p=0.01). The combined predictive accuracy of these 2 measures for conversion by 3 years was 86%.

| DP Devanand, GP Pradhanan, X Liu, A Khandji, S DeSanti, JG, H Rotnich, GH Pelton, LS Hong, RR Mayeux, Y Stern, MH Tabert, MD Leon (2007) Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. [9] | Baseline brain MRI was done in 139 patients with MCI broadly defined, and 63 healthy controls followed for an average of 5 years (range 1 to 9 years) | Exposures: Hippocampal and entorhinal cortex volumes from brain MRI. Outcomes: Conversion to AD. | Hippocampal and entorhinal cortex volumes were each largest in controls, intermediate in MCI non-converters, and smallest in MCI converters to AD (37 of 139 patients converted to AD). In separate Cox proportional hazards models, covarying for intracranial volume, smaller hippocampal volume (RR 3.62, 95% CI 1.93, 6.80; p<0.0001) and entorhinal cortex volume (RR 2.43, 95% CI 1.56, 3.79; p<0.0001) each predicted time to conversion to AD. Similar results were obtained for hippocampal and entorhinal cortex volume in patients with MCI with MMSE ≥27/30 (21% converted to AD) and in the subset of patients with amnestic MCI (35% converted to AD). In the total patient sample, when both hippocampal and entorhinal volume were entered into an age-stratified Cox model with gender, MMSE, education, and intracranial volume, smaller hippocampal volume (RR 2.21, 95% CI 1.14, 4.29; p<0.02) and entorhinal cortex volume (RR 2.48, 95% CI 1.54, 3.87; p<0.0002) predicted time to conversion to AD. Similar results were obtained in a Cox model that also included SRT delayed recall and WAIS-R Digit Symbol as predictors. Based on logistic regression models in the 3-year follow-up sample, for a fixed specificity of 80%, the sensitivities for MCI conversion to AD were as follows: age 43.3%, MMSE ≤27%, age ≥MMSE ≤27%, age ≥MMSE ≤27% SRT delayed recall ≤WAIS-R Digit Symbol 80.6% (79.6% correctly classified), hippocampal + entorhinal cortex 66.7%: age ≥MMSE ≤27% SRT delayed recall ≤WAIS-R Digit Symbol + hippocampus + entorhinal cortex 83.3% (86.8% correctly classified).|

AD, Alzheimer’s disease; MCI, mild cognitive impairment; MMSE, Mini-Mental Status Exam; MRI, magnetic resonance imaging; OR, odds ratio; RR, risk ratio; SRT, Selective Reminding Test; WAIS-R Digit Symbol, Wechsler Adult Intelligence Scale–Revised Digit Symbol Test.
Table 3
Summary of most cited articles reporting on the progression of late onset Alzheimer’s disease. The studies are based in a cohort of persons with late onset Alzheimer’s disease in New York City (PI: Y. Stern)

<table>
<thead>
<tr>
<th>Study [Ref]</th>
<th>Participants/design</th>
<th>Exposures/outcomes</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>N Scarmeas, SM Albert, JJ Manly, Y Stern (2006) Education and rates of cognitive decline in incident Alzheimer’s disease. [5]</td>
<td>During the course of a community-based multiracial prospective cohort study of individuals aged ≥65 years living in New York, 312 patients were diagnosed with incident AD and were followed overall for 5.6 (up to 13.3) years</td>
<td>The subjects received an average of 3.7 (up to 9) neuropsychological assessments consisting of 12 individual tests. With the aid of a normative sample, a standardized composite cognitive score, as well as individual cognitive domain scores were calculated. GEE models were used to examine the association between education and rates of cognitive decline</td>
<td>Composite cognitive performance declined by 9% of a standard deviation per year. Rates of decline before and after AD incidence were similar. For each additional year of education there was 0.3% standard deviation lower composite cognitive performance for each year of follow-up. The association between higher education and faster decline was noted primarily in the executive-speed (0.6%) and memory (0.5%) cognitive domains and was present over and above age, gender, ethnicity, differential baseline cognitive performance, depression, and vascular comorbidity</td>
</tr>
<tr>
<td>N Scarmeas, JA Luchsinger, R Mayeux, Y Stern (2007) Mediterranean diet and Alzheimer’s disease mortality. [12]</td>
<td>A total of 192 community-based individuals in New York who were diagnosed with AD were prospectively followed every 1.5 years Adherence to the MeDi (0–9 point scale with higher scores indicating higher adherence) was the main predictor of mortality in Cox models that were adjusted for period of recruitment, age, gender, ethnicity, education, APOE genotype, calorie intake, smoking, and BMI</td>
<td>85 AD patients (44%) died during the course of 4.4 (±3.6, 0.2–13.6) years of follow-up. In unadjusted models, higher adherence to MeDi was associated with lower mortality risk (for each additional MeDi point HR 0.79; 95% CI 0.69–0.91; ( p=0.001 )). This result remained significant after controlling for all covariates (0.76; [0.65–0.89]; ( p=0.001 )). In adjusted models, as compared to AD patients at the lowest MeDi adherence tertile, those at the middle tertile had lower mortality risk (0.65; [0.38–1.09]; 1.33 years longer survival), while subjects at the highest tertile had an even lower risk (0.27 [0.10–0.69]; 3.91 years longer survival; ( p ) for trend 0.003)</td>
<td></td>
</tr>
<tr>
<td>JC Amatniek, WA Huxter, C DeCastillo-Castaneda, DM Jacobs, K Mandre, K Bell, M Albert, J Braun, Y Stern (2006) Incidence and predictors of seizures in patients with Alzheimer’s disease. [11]</td>
<td>Mild AD patients were prospectively followed at 6-month intervals Estimate incidence of unprovoked seizures, compare age-specific risk of unprovoked seizures with population norms, and identify characteristics at baseline (demographics, duration and severity of AD, physical and diagnostic test findings, and comorbid medical and psychiatric conditions) influencing unprovoked seizure risk. Review of study charts and medical records supplemented coded end-point data</td>
<td>The cumulative incidence of unprovoked seizures at 7 years was nearly 8%. In all age groups, risk was increased compared with a standard population, with an 87-fold increase in the youngest group (age 50–59 years) and more than a threefold increase in the oldest group (age 85+ years). In multivariate modeling, independent predictors of unprovoked seizures were younger age (HR, 0.89 per year increase in age; 95% CI, 0.82–0.97), African-American ethnic background (HR, 7.35; 95% CI, 1.42–37.98), more-severe dementia (HR, 4.15; 95% CI, 1.06–16.27), and focal epileptiform findings on EEG (HR, 73.6; 95% CI, 1.78–3075.22)</td>
<td></td>
</tr>
</tbody>
</table>
Table 3 (Continued)

<table>
<thead>
<tr>
<th>Study [Ref]</th>
<th>Participants/design</th>
<th>Exposures/outcomes</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP Helzner, JA Luchsinger, N Scarmeas, N Cosentino, AM Brickman, MM Glymour, Y Stern (2009) Contribution of vascular risk factors to disease progression in Alzheimer's disease. [6]</td>
<td>156 incident AD patients (mean age 83 years at diagnosis) were prospectively followed every 1.5 years</td>
<td>The exposures were vascular factors including medical history (heart disease, stroke, diabetes, hypertension), smoking, and pre-diagnosis blood lipid measurements (total cholesterol, HDL-C, LDL-C, and triglycerides). The main outcome was change in a composite score of cognitive ability from diagnosis on to disease progression.</td>
<td>In GEE models adjusted for age, race/ethnicity, and education, higher cholesterol (total and LDL-C), and diabetes history were associated with faster cognitive decline. A 10-unit increase in cholesterol and LDL-C was associated with a 10% of a standard deviation decrease in cognitive score per year of follow-up (p = 0.001 for total cholesterol, p = 0.001 for LDL-C). HDL and triglycerides were not associated with rate of decline. Diabetes history was associated with an additional 5% of a standard deviation decrease in cognitive score per year (p = 0.05). History of heart disease and stroke were associated with cognitive decline among APOE ε4 carriers only. In a final GEE model that included HDL-C, LDL-C, and diabetes, only higher LDL-C was independently associated with faster cognitive decline.</td>
</tr>
</tbody>
</table>

AD, Alzheimer's disease; APOE, apolipoprotein E; BMI, body mass index; GEE, general estimating equation; HDL-C, high density lipoproteins; HR, hazards ratio; LDL-C, low density lipoproteins; MeDi, Mediterranean diet; RR, risk ratio.
exposures not only potentially affect the risk of AD but also its course and mortality. The study examining seizures shows clinicians following persons with AD that they should expect the need to treat seizures and provided potential predictors for this complication. The study on education and AD course provides important support for the cognitive reserve hypothesis that is discussed next.

**COGNITIVE RESERVE AND ALZHEIMER'S DISEASE**

This article was the only one out of the 12 to review a topic in AD [8] suggesting a framework for the study of an important hypothesized modifier of its clinical presentation. Epidemiologic evidence suggests that individuals with higher intelligence quotient, education, occupational attainment, or participation in leisure activities have a reduced risk of developing AD. The concept of cognitive reserve posits that individual differences in how tasks are processed provide differential reserve against brain pathology or age-related changes. This may take two forms, neural reserve and neural compensation. In neural reserve, pre-existing brain networks that are more efficient or have greater capacity may be less susceptible to disruption. In neural compensation, alternate networks may compensate for pathology's disruption of pre-existing networks. Imaging studies have begun to identify the neural substrate of cognitive reserve. Because cognitive reserve may modulate the clinical expression of AD pathology, it is an important consideration in studies of 'preclinical' AD and treatment studies. There is also the possibility that directly enhancing cognitive reserve may help forestall the diagnosis of AD.

The AD field is at a juncture at which there is growing acceptance that this disease is more heterogeneous than originally thought and remains uncertainty about the validity of the hypothesis that postulates that brain amyloid deposition is the main culprit. Other aspects such as vascular disease are increasingly recognized as contributors to AD, but even this element has proven insufficient to explain AD risk. In this context, the concept of cognitive reserve has emerged as an important modifier of disease expression that requires further study. Research is needed to better characterize the measurement of this concept and to understand how it affects AD risk. For example, a sensitive measure of cognitive reserve could help the assessment of its modulation of risk factors such as the Mediterranean diet, could improve predictive models for conversion from MCI to AD, and could help better predict progression of AD.

**SUMMARY**

The 12 articles summarized in this review made important contributions to the field of AD in the last 5 years. Four of the articles established the Mediterranean diet as food consumption pattern that may prevent AD in addition to physical activity. Two of the articles advanced our knowledge of predictors of conversion from MCI to dementia. Four of the articles provided important knowledge of risk factors for the progression of AD and its complications. Lastly, one of the articles laid the theoretical framework for the study of cognitive reserve, an important modifier of the manifestation of AD.

**ACKNOWLEDGMENTS**

The work summarized in this article was supported by the following grants from the National Institute of Health: AG07232, AG15473, AG090029, AG07702, AG15294, RR00645, AG17761, AG12101, MH5735, MH35636, MH55646, P50 AG08702, AG08051, AG02615, AG07232, RR006458. The work was also supported by the Alzheimer’s Association, the Blanche Hooker Rockefeller Foundation, Charles S. Robertson Gift from the Banbury Fund, the Canadian Institutes of Health Research, the Howard Hughes Medical Institute, the Canadian Institutes of Health Research-Japan Science and Technology Trust, the Alzheimer Society of Ontario, the Canada Foundation for Innovation, the Ontario Research and Development Challenge Fund, the Ontario Mental Health Foundation, Genome Canada and the Alzheimer Society of Canada (PSH). Authors’ disclosures available online (http://www.j-alz.com/disclosures/view.php?id=1446).

**REFERENCES**